A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Aragon Pharmaceuticals, Inc.
A observational or N/A phase clinical study on Metastatic Castration-Resistant Prostate Cancer and Prostatic Neoplasms, this trial is ongoing. The trial is conducted by Aragon Pharmaceuticals, Inc. and has accumulated 70 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone \[AAP\] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment \[ie, for up to an expected duration of approximately 18 months\] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and...
This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone \[AAP\] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment \[ie, for up to an expected duration of approximately 18 months\] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and to complete the PK analysis up to the cutoff date. All participants will continue on study (ie, to receive treatment) until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. The end of the study is defined when all participants have completed treatment. Participant's safety will be monitored throughout the study.
Status Flow
Change History
70 versions recorded-
Apr 13, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
▶ Show 65 earlier versions
-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
-
Mar 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.
Contact Information
- Aragon Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .